Compare DexCom, Inc. (DXCM) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wells Fargo & Co — how do they compare? DexCom, Inc. trades at $77.75 (market cap $28.06B), while Wells Fargo & Co trades at $87.79 (market cap $265.03B). The key difference: Wells Fargo & Co is far larger — about 9.4× DexCom, Inc.'s market cap, and Wells Fargo & Co pays a 2.06% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WFC | |
|---|---|---|
Market Cap | $28.06B | $265.03B |
Sector | Health | Financials |
52-Week High | $89.53 | $96.40 |
52-Week Low | $54.84 | $73.42 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Wells Fargo (WFC) stock trades at $85.525, down 2.48% on the day, following a strong Q2 2026 earnings beat where EPS of $1.96 exceeded the $1.73 estimate. The technical outlook is bullish with price near the pivot point of $86, while fundamentals show improving profitability with a 25.97% net income margin. Analyst sentiment remains positive with a $97.36 consensus price target, though recent cash flow trends show operational challenges.
The outlook for WFC is cautiously optimistic with growth initiatives in wealth management and investment banking driving revenue. Key risks include net interest margin pressure and volatile cash flows, while the 12.72 P/E ratio offers reasonable valuation. Upside potential exists toward the $97.36 analyst target if earnings momentum continues post-asset cap removal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
